pubmed.ncbi.nlm.nih.gov

Screening of cervical neoplasia in HIV-infected women in India - PubMed

️Tue Jan 01 2013

Screening of cervical neoplasia in HIV-infected women in India

Smita Joshi et al. AIDS. 2013.

Abstract

Objective: To evaluate an accurate, affordable, and feasible method to screen and treat HIV-infected women so that cervical cancer can be prevented among them.

Design: A cross-sectional study was conducted in India in which eligible HIV-infected women underwent visual inspection with acetic acid (VIA), visual inspection with Lugol's iodine (VILI), cytology, human papillomavirus (HPV) testing, and colposcopy.

Methods: We screened women with cytology, HPV testing, VIA, and VILI. All screened women had colposcopy and women with colposcopic abnormalities had directed biopsies. Women with suspected cervical intraepithelial neoplasia (CIN) on colposcopy were treated with cold coagulation or loop excision. Sensitivity, specificity, and predictive values of the screening tests were calculated.

Results: : Among 1128 women screened, 55 (4.9%) had CIN2-3 lesions. Sensitivity for VIA, VILI, cytology at atypical squamous cells of undetermined significance (ASCUS) threshold and HPV testing was 83.6, 89.1, 63.3, and 94.6%, and specificity was 88.8, 89.3, 94.5, and 77.4%, respectively, in detecting CIN2/3 lesions. Cytology had significantly lower sensitivity and higher specificity than VIA, VILI, and HPV testing. Sequential testing with VIA/VILI, HPV testing/VIA, HPV testing/VILI, and HPV testing/VIA/VILI had more balanced sensitivity and specificity than the single tests. Cold coagulation was well tolerated and cured 80% of CIN2-3 based on preliminary results at 6-month to 1-year follow-up periods.

Conclusions: Sequential testing with VIA and VILI is the most feasible screening approach for cervical cancer screening in HIV-infected women in low-resource countries. When HPV testing becomes feasible and affordable, HPV testing followed by VIA/VILI may be considered.

PubMed Disclaimer

Cited by

Mobile Screening Unit (MSU) for the Implementation of the 'Screen and Treat' Programme for Cervical Cancer Prevention In Pune, India.
Joshi S, Muwonge R, Kulkarni V, Lucas E, Kulkarni S, Kand S, Mandolkar M, Baig M, Wankhede S, Surwase K, Pardeshi D, Basu P, Rengaswamy S. Joshi S, et al. Asian Pac J Cancer Prev. 2021 Feb 1;22(2):413-418. doi: 10.31557/APJCP.2021.22.2.413. Asian Pac J Cancer Prev. 2021. PMID: 33639655 Free PMC article.
Feasibility of adjuvant self-administered intravaginal 5-fluorouracil cream following primary treatment of cervical intraepithelial neoplasia grade 2 or 3 among women living with HIV in Kenya: study protocol for a pilot trial.
Mungo C, Bukusi E, Kirkland GE, Ogollah C, Rota G, Omoto J, Rahangdale L. Mungo C, et al. medRxiv [Preprint]. 2023 Dec 14:2023.12.13.23299916. doi: 10.1101/2023.12.13.23299916. medRxiv. 2023. PMID: 38168442 Free PMC article. Preprint.
PCR and Genotyping for HPV in Cervical Cancer Patients.
Prakash P, Patne SC, Singh AK, Kumar M, Mishra MN, Gulati AK. Prakash P, et al. J Glob Infect Dis. 2016 Jul-Sep;8(3):100-7. doi: 10.4103/0974-777X.188591. J Glob Infect Dis. 2016. PMID: 27621560 Free PMC article.
Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus.
Luckett R, Mogowa N, Li HJ, Erlinger A, Hacker MR, Esselen K, Feldman S, Shapiro R, Morroni C, Ramogola-Masire D. Luckett R, et al. Obstet Gynecol. 2019 Oct;134(4):840-849. doi: 10.1097/AOG.0000000000003496. Obstet Gynecol. 2019. PMID: 31503167 Free PMC article.
Are we missing opportunities to prevent cervical cancer in HIV-infected women in India?
Joshi S, Kulkarni V, Gangakhedkar R, Sankaranarayanan R. Joshi S, et al. Indian J Med Res. 2015 Nov;142(5):610-3. doi: 10.4103/0971-5916.171292. Indian J Med Res. 2015. PMID: 26658598 Free PMC article. No abstract available.

Screening of cervical neoplasia in HIV-infected women in India - PubMed